Fairvalue-Calculator Fairvalue-Calculator
EN DE

Tanvex BioPharma, Inc (6541) Fair Value & Analysis

Healthcare · TW · Market cap 10.5B TWD

Price45.25 TWD
Fair Value14.40 TWD
Upside-68.2%
Quality95/100
Evidence: Low Range 10.74 TWD – 21.49 TWD

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Tanvex BioPharma, Inc (6541) currently trades at 45.25 TWD, while our model-based Fair Value estimate is 14.40 TWD — implying the stock looks roughly 68.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Tanvex BioPharma, Inc., a pharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biopharmaceuticals with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. It also engages in contract development and manufacturing of biological medicines. The company was founded in 2011 and is headquartered in George Town, the Cayman Islands.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Tanvex BioPharma, Inc (6541) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 14.40 TWD versus a price of 45.25 TWD — about −68% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6541?
Our 21-model fair value for Tanvex BioPharma, Inc is 14.40 TWD (as of Jun 25, 2026), built from audited fundamentals. The current price is 45.25 TWD.
What is the quality score of 6541?
Tanvex BioPharma, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.